Alpha 2.0
Login Register
» Articles » PMID: 36004699

Use of Sodium Glucose Co-transporter 2 Inhibitors in Acute Heart Failure: a Practical Guidance

Overview
Journal ESC Heart Fail
Date 2022 Aug 25
PMID 36004699
Authors
Joao Pedro Ferreira
Joana Pimenta
Brenda Moura
Carlos Aguiar
Fatima Franco
Affiliations
Soon will be listed here.
Abstract

Aims: Heart failure (HF) is the most frequent cause of hospital admission among patients 65 years or older. Patients hospitalized for acutely decompensated chronic HF and 'de novo' acute heart failure (AHF) continue to experience unacceptably high post-discharge readmission and mortality rates.

Methods And Results: Until recently, trials had failed to improve outcome in patients with AHF irrespective of ejection fraction with exception of sodium-glucose co-transporter 2 inhibitors (SGLT2i) that improved clinical outcomes in patients hospitalized for AHF in the Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure (EMPULSE) and in the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trials.

Conclusions: This document reviews the potential utility of SGLT2i in patients hospitalized for AHF.

Citing Articles

Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians.

Monzo L, Ferrari I, Cicogna F, Tota C, Cice G, Girerd N Eur Heart J Suppl. 2023; 25(Suppl C):C309-C315.

PMID: 37125324 PMC: 10132577. DOI: 10.1093/eurheartjsupp/suad055.

Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance.

Ferreira J, Pimenta J, Moura B, Aguiar C, Franco F ESC Heart Fail. 2022; 9(6):4344-4347.

PMID: 36004699 PMC: 9773770. DOI: 10.1002/ehf2.14090.

References
1.
Savarese G, Lund L . Global Public Health Burden of Heart Failure. Card Fail Rev. 2017; 3(1):7-11. PMC: 5494150. DOI: 10.15420/cfr.2016:25:2. View
2.
Ambrosy A, Fonarow G, Butler J, Chioncel O, Greene S, Vaduganathan M . The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014; 63(12):1123-1133. DOI: 10.1016/j.jacc.2013.11.053. View
3.
Velazquez E, Morrow D, DeVore A, Duffy C, Ambrosy A, McCague K . Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2018; 380(6):539-548. DOI: 10.1056/NEJMoa1812851. View
4.
Packer M . Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovasc Res. 2020; 117(1):74-84. DOI: 10.1093/cvr/cvaa064. View
5.
Fonseca C, Brito D, Cernadas R, Ferreira J, Franco F, Rodrigues T . For the improvement of Heart Failure treatment in Portugal - Consensus statement. Rev Port Cardiol. 2016; 36(1):1-8. DOI: 10.1016/j.repc.2016.10.006. View